Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 5, Issue 4, Pages 353-366Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425250902877698
Keywords
acetylator polymorphism; N-acetyltransferase 1; N-acetyltransferase 2; personalized medicine; single nucleotide polymorphisms
Funding
- National Cancer Institute [R01-CA034627]
- National Institute of Environmental Health Sciences [P30-ES014443]
- National Institute of Child Health and Development [U10-HD045934]
Ask authors/readers for more resources
Arylamine N-acetyltransferase 1 and 2 exhibit single nucleotide polymorphisms in human populations that modify drug and carcinogen metabolism. This paper updates the identity, location and functional effects of these single nucleotide polymorphisms and then follows with emerging concepts for understanding why pharmacogenetic findings may not be replicated consistently. Using this paradigm as an example, laboratory-based mechanistic analyses can reveal complexities such that genetic polymorphisms become biologically and medically relevant when confounding factors are more fully understood and considered. As medical care moves to a more personalized approach, the implications of these confounding factors will be important in understanding the complexities of personalized medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available